key: cord-0057398-1u4pdk0m
authors: Rizk, Mina M.; Herzog, Sarah; Dugad, Sanjana; Stanley, Barbara
title: Suicide Risk and Addiction: The Impact of Alcohol and Opioid Use Disorders
date: 2021-03-14
journal: Curr Addict Rep
DOI: 10.1007/s40429-021-00361-z
sha: 160ee44a7c67050341ef8879033c1e4bc0ea13b3
doc_id: 57398
cord_uid: 1u4pdk0m

PURPOSE OF REVIEW: Suicide is a major public health concern and a leading cause of death in the US. Alcohol and opioid use disorders (AUD/OUD) significantly increase risk for suicidal ideation, attempts, and death, and are the two most frequently implicated substances in suicide risk. We provide a brief overview of shared risk factors and pathways in the pathogenesis of AUD/OUD and suicidal thoughts and behaviors. We also review clinical recommendations on inpatient care, pharmacotherapy, and psychotherapeutic interventions for people with AUD/OUD and co-occurring suicidal ideation and behavior. RECENT FINDINGS: Among people with an underlying vulnerability to risk-taking and impulsive behaviors, chronic alcohol intoxication can increase maladaptive coping behaviors and hinder self-regulation, thereby increasing the risk of suicide. Additionally, chronic opioid use can result in neurobiological changes that lead to increases in negative affective states, jointly contributing to suicide risk and continued opioid use. Despite significantly elevated suicide risk in individuals with AUD/OUD, there is a dearth of research on pharmacological and psychosocial interventions for co-occurring AUD/OUD and suicidal ideation and behavior. SUMMARY: Further research is needed to understand the effects of alcohol and opioid use on suicide risk, as well as address notable gaps in the literature on psychosocial and pharmacological interventions to lower risk for suicide among individuals with AUD/OUD.

Suicide rates rose by 35% in the US over the past two decades [1] despite significant efforts to reverse this pattern by identifying risk factors and preventative interventions [2] . While mood disorders are among the most important risk factors for suicide [3] [4] [5] , comorbidity with alcohol and substance use disorders (AUD/SUD) vastly increases vulnerability to suicidal ideation [6, 7] , attempts [8, 9] , and deaths [5, 10, 11] . Additionally, suicidal ideation and behavior are significant clinical concerns among those seeking treatment for AUD/SUD [12] , and risk for highly lethal suicide attempts remains to be elevated even after remission from SUD [13] . While all substances elevate the risk for suicidal behavior, alcohol and opioids are the most common substances identified in suicide decedents (22% and 20%, respectively), far above rates of marijuana (10.2%), cocaine (4.6%), and amphetamines (3.4%) [14•]. In this review, we summarize literature on the role of AUD and opioid use disorder (OUD) in contributing toward the risk of suicidal thoughts and behavior and discuss treatment interventions.

psychiatric disorders [18] . Cross-national studies indicate a linear relationship between suicide rates and per-capita alcohol consumption [19, 20] , suggesting that alcohol may be a key factor in suicide. Indeed, rates of alcohol misuse have escalated over the last two decades [21, 22] in parallel with rising suicide rates [23, 24] . Since 2001, past-year prevalence of high-risk drinking has increased by 29.9%, and alcohol use disorder (AUD) by an alarming 49.4% [21] . Importantly, rising rates of alcohol misuse are accompanied by a 35% increase in alcohol-related suicide deaths [23] .

Two forms of alcohol use are implicated in the elevated risk for suicidal thoughts and behavior-acute alcohol intoxication and chronic alcohol use or dependence [25, 26] . The 24-hour period following alcohol intoxication is associated with a seven-fold increase in the risk for suicidal behavior [27] . Moreover, alcohol intoxication is related to greater lethality of attempt methods, making suicide fatalities more likely [28] . Over a third of suicide decedents test positive for alcohol; 63.5% of whom have blood concentrations demonstrating intoxication [29] , and more suicide decedents test positive for alcohol than other substances. Chronic alcohol use/dependence is similarly an important population-level risk factor for suicidal behavior [17, 30] . AUD is associated with a 10-fold higher risk for suicide compared to the general population [10] and trails mood disorders as the second most common psychiatric diagnosis in complete suicides [31] .

Conceptual models accounting for causal mechanisms between AUD and suicide risk largely fall into two categories: a proximal pathway through the acute effects of alcohol intoxication, and a distal (i.e., predisposing) pathway through chronic alcohol use [32] . For example, the acute effects of alcohol intoxication, e.g., increased dysphoria, myopia, agitation, and impaired perception and motor control [33, 34] , may render an individual prone to risk-taking or impulsive behavior and less likely to seek alternative solutions to self-regulate [25], thereby precipitating suicidal behavior. Intoxication also promotes behavioral disinhibition and affective numbing, potentially lessening fear of death that might otherwise act as a psychological barrier to suicide [35] . Suicide and alcohol use also share indirectly precipitating risk factors. For example, consistent with models of suicide as an escape aversive selfawareness [36] , AUD and suicidal behavior may not be causally related but arise as a function of a third proximal factor such as motivation to avoid painful internal states [37] . Accordingly, acute intake might reflect maladaptive efforts at coping with negative affect [38] that paradoxically exacerbate dysphoria and suicidal ideation due to the depressogenic effects of alcohol [25] . Suicidal urges might prompt acute alcohol intoxication, for instance, as a means to lower inhibitions for self-inflicted violence.

Alcohol and suicide also share a number of distal, predisposing risk factors that may interact with immediate, proximal factors to produce suicidal outcomes. For example, according to the stress-diathesis model of suicidal behavior [39, 40] , alcohol use might trigger suicidal behavior in those with an underlying vulnerability, such as a propensity toward stressreactive impulsivity. Externalizing traits in particular may reflect an underlying vulnerability that promotes both impulsive aggression and suicidal behavior [41] , and might also dispose an individual toward alcohol misuse [42, 43] . Additionally, childhood maltreatment is a shared predisposing factor for both alcohol misuse and suicidality [44, 45] that is likewise associated with impulsive and aggressive behavior [46] . Over time, chronic alcohol use can heighten the risk for suicide by promoting social isolation, corroding relationships and support systems, and precipitating or aggravating psychosocial stressors (e.g., homelessness, financial insecurity) [25, 32] . Indeed, heavy drinking is associated with aggressive behavior, intimate partner violence, economic hardship, and job loss [47] [48] [49] , all of which predict both suicide and alcoholrelated deaths [50] [51] [52] . Of particular concern in older adults for whom physical illness and disability constitute a major risk factor for suicide [53] [54] [55] [56] , chronic AUD can also accelerate aging processes [57, 58] and produce toxic physiological effects [59] . Moreover, cognitive deficits that emerge from repeated alcohol misuse may impair emotion regulation, decision-making and behavioral control [60] , contributing to increased suicide risk [61] .

Individuals with AUD share a number of neurobiological characteristics with suicidal individuals. Evidence of impaired serotonin (5-hydroxytryptamine; 5-HT) transmission has been found postmortem in the brains of suicide decedents [62] , as well as in the cerebrospinal fluid (CSF) of nonfatal attempters [63, 64] . Reductions in binding of 5-HT 1A receptors and serotonin transporter have likewise been found in prefrontal brain regions of alcoholic individuals [65] . Importantly, serotonergic dysfunction may be central to the pathogenesis of depression [66] , specifically with regard to 5-HT 1A and 5-HT 1B receptors [67] thought to play a role in mood and reward sensitivity, and regulation of impulsivity and aggression [67] . Thus, serotonergic dysfunction may reflect a common pathway to suicidal outcomes and AUD, perhaps mediated by underlying depression or impulsive aggression. Studies of serotonin metabolites support this; for example, in high-and low-lethality attempters, trait aggression is related to lower concentrations of CSF 5hydroxyindolacetic acid (5HIAA; a major metabolite of serotonin), and high lethality attempters demonstrated lower CSF 5-HIAA [68] . Lower concentrations of 5HIAA have also been found in alcoholic individuals compared to controls [69] and in impulsive violent offenders compared to premeditated offenders [70] . In the latter study, the lowest levels of CSF-5HIAA were found in impulsive offenders with a past suicide attempt, perhaps suggesting that impulsivity and suicidality are independently and additively related to serotonergic dysfunction.

AUD and suicidal behavior might share a genetic association with the promoter region of the serotonin transporter gene (SLC6A4), referred to as 5-HTTLPR [71] . The functional polymorphism of the 5-HTTLPR, specifically, the "short" (S) allele, is linked to a deficiency in serotonin reuptake and has been associated with suicidal behavior [72] , particularly multiple and highly lethal attempts. The S allele of SLC6A4 has also been found in greater frequency in patients with severe alcohol dependence compared to controls [73] and is related to greater novelty-seeking in individuals with alcohol dependence compared to those without the S variant [74] .

Individuals with history of suicidal behavior and those with AUD exhibit overlapping brain morphometric alterations. Suicidal behavior is associated with reductions in gray matter volume in various parts of the dorsolateral prefrontal cortex (dlPFC) implicated in decision-making and inhibitory control [75, 76] . Persons using alcohol likewise show reduced gray matter volume in these areas [77] [78] [79] , as well as reward-related regions, such as the amygdala, anterior insula, and nucleus accumbens [80] . Additionally, adolescents with both AUD and suicidality have smaller prefrontal cortices compared to controls [81, 82] . Diffusion tensor imaging studies also show lower white matter integrity in the frontal and limbic regions in both suicide attempters [83, 84] and youths with AUD [78, 85] . Those structural brain changes in gray matter volume and white matter tracts integrity may be related to the neurotoxic effects of alcohol [78, 86, 87] , with some evidence suggesting a dose-response relationship between white matter microstructural integrity and peak blood-alcohol concentrations in alcohol users [85] .

Dysfunction of the biological stress response as suggested by hyperactive hypothalamic-pituitary-adrenal (HPA) axis responses has been evinced in both heavy alcohol users [88] [89] [90] and suicidal individuals [91] alike. Specifically, a subtype of suicide attempters high in trait impulsivity and aggression exhibited heightened cortisol responses to a lab-induced social stressor, compared to suicide attempters low on either aggression, impulsivity, or both [92, 93] . Hyperactive cortisol responses have also been demonstrated in individuals with major depression [71] , particularly in relation to symptoms of psychomotor agitation [94] , and in individuals with highly variable patterns of suicidal ideation compared to those with stable suicidal thoughts [95] . Moreover, acute alcohol intoxication is associated with stress-like increases in cortisol response [96] . Conceivably, HPA axis dysregulation may heighten the risk of both alcohol misuse and suicidality.

Alternatively, alcohol intake might stimulate HPA activity [97] that then contributes to greater likelihood of risky, impulsive, or suicidal behavior. To this point, individuals who demonstrated increased sedative effects with higher dosing of alcohol also mounted greater cortisol responses to a social stress test, suggesting that alcohol intoxication contributes to hyperreactive cortisol responses [98] . Serotonergic dysfunction might also be a cross-cutting link between alcoholism, suicide, and HPA axis dysregulation [99] , as serotonergic systems regulate HPA functioning by inhibiting or stimulating stressrelated activity [100] .

There is a pressing need to develop effective interventions for co-occurring suicidal ideation and behavior and alcohol misuse because this high-risk population tends to have a more severe course of alcoholism, increased psychiatric and substance use comorbidity, and greater psychosocial impairment (e.g., unemployment, divorce, lower educational attainment), than individuals with AUD alone [101] [102] [103] . Additionally, suicide decedents with AUD tended to drink chronically until their deaths and had a recent alcohol binge in close proximity to, or as part of, a suicide attempt [104] .

Clinical recommendations suggest inpatient care for individuals with alcohol misuse who present with suicidal plans or intent, preferably in a dual-diagnosis facility (i.e., treatment setting for AUD/SUD and comorbid mental illness) [104, 105] . Evidence suggests that suicidal individuals with comorbid AUD significantly benefit from inpatient treatment relative to outpatient settings [106] . Additionally, acutely intoxicated individuals with suicidal urges appear to stabilize quickly in inpatient care [107] . However, relapse and suicidal behavior following discharge remain significant concerns [108] . Transfer to another inpatient setting following acute stabilization may decrease the risk of postdischarge suicide attempts [109] , and longer treatment courses, whether inpatient or outpatient, may lower the posttreatment risk of suicidal behavior [110] . Notably, impulsive suicide attempts may be a strong indicator of relapse risk after discharge. Individuals with alcohol dependence who are hospitalized for an impulsive suicide attempt have higher rates of postdischarge relapse, and relapse faster, than those without an impulsive attempt [111] . This lends support to the clinical utility of targeting suicidality and alcohol misuse simultaneously in the acute stages of treatment.

Pharmacological Interventions There are many FDAapproved medications for treatment of depression [112] and primary among them are selective serotonin reuptake inhibitors (SSRIs). As yet, however, there are no FDAapproved medications specifically indicated for suicidal ideation, urges, or behavior [113] . A few pharmacotherapies have been approved for the treatment of alcohol misuse [114, 115] . They include disulfiram, which produces aversive symptoms following alcohol intake; acamprosate, thought to mitigate withdrawal-related symptoms; and naltrexone, a nonselective opiate receptor antagonist that reduces alcohol cravings. These drugs primarily operate by targeting reinforcement mechanisms involved in alcohol misuse; however, extendedrelease naltrexone has also shown some benefits in reducing attendant anxiety and depressive symptoms [116] .

Although not specifically indicated for suicidal ideation or behavior, SSRIs have been used with some success in decreasing suicidal ideation alongside other depressive symptoms, and reducing alcohol misuse in depressed alcohol users [101, [117] [118] [119] . SSRIs consistently produce a modest 15-20% reduction in alcohol consumption [120] , however intraindividual reductions in alcohol intake range widely from 10 to 70% [120] . In addition to SSRIs, tricyclic antidepressants are thought to mitigate depressive-like alcohol withdrawal symptoms [121] and may be effective for co-occurring depression and AUD [122, 123] . Double-blinded, randomized, placebo-controlled trials for co-occurring MDD/dysthymia and AUD indicate that antidepressants-particularly non-SSRIs-outperform placebo in the treatment of depression [122] , while SSRIs only demonstrate efficacy when restricted to participants without AUD [124] . Additional meta-analytic research similarly suggests lower performance of SSRIs relative to tricyclics in comorbid MDD and AUD/SUD [119, 125] , but results should be interpreted cautiously given the potentially mediating roles of study design and sample selection. Additionally, findings regarding depressive symptom reduction are equivocal when controlling for study quality and bias [126] , and antidepressants may not be justified for treatment of alcohol misuse in the absence of MDD [118, 127] . Lastly, studies combining pharmacotherapies for depression and alcohol dependence (e.g., sertraline and naltrexone) suggest better results for mood symptoms and abstinence than either mood or AUD treatment alone [123, 128] . To date, however, there are insufficient trials comparing one medication to another [126] , and few that examine the effects of pharmacotherapy on suicidality in alcohol users.

Psychotherapeutic Interventions Brief interventions for suicidal crises (e.g., Safety Planning Intervention; SPI) often implemented in healthcare settings typically involve a written compilation of STB triggers, coping strategies, and sources of support [129] . Similar variations may include a risk assessment component (e.g., ED-SAFE) or intermittent outreach (e.g., SPI+) [130] . These interventions have shown success in reducing imminent suicide risk [52] and may be potentially adapted to address simultaneous risk of alcohol misuse.

However, there is a dearth of research evaluating their effectiveness in co-occurring suicidality and AUD.

A variety of longer-term psychotherapies for AUD may be relevant in populations with co-occurring suicidality. Motivational enhancement therapy (MET) is a time-limited intervention that utilizes motivational interviewing (MI) principles to resolve ambivalence about treatment engagement and clarify goals relating to alcohol use [131, 132] . Cognitive behavioral therapy (CBT) for co-occurring mood and AUD focuses on dysfunctional, distorted, or self-defeating schemas or beliefs that may be contributing, jointly or severally, to depressed mood, suicidality, and alcohol misuse [133] . MI and CBT interventions have shown the greatest success among psychotherapeutic interventions used in populations with co-occurring alcohol misuse and depression and/or anxiety, even in brief interventions [134] , and longer-term treatments produce still better outcomes. In combination, MET/CBT interventions have shown effectiveness in adolescent populations with co-occurring MDD and AUD [135] . Other interventions, such as relapse prevention therapy (RPT) and contingency management (CM), directly target the psychological reinforcement mechanisms that maintain addictive behavior. While they have been effective in populations with AUD/SUDs, there is limited evidence of their utility in co-occurring suicidality/depression and alcohol misuse [136] .

Psychotherapy in combination with psychopharmacological treatment may also benefit from the advantages of each of these modalities [137] . For example, in a study of adolescents with AUD receiving fluoxetine for depression, those who also received a manualized CBT/MET protocol had superior outcomes for depression and alcohol-related symptoms compared to those who did not [135] . However, extant data are not conclusive [115•] , and further research is necessary to evaluate the combined effectiveness of psychotherapy and pharmacology in co-occurring suicidality and AUD [138] .

The US is currently in the midst of an opioid epidemic. In 2016 alone, 11.8 million people misused opioids and 42,000 died by opioid-overdose [139] . Recent research suggests that a suicidal element may play a significant role in opioid overdose deaths [140, 141] . People who use opioids are 14 times more likely to die by suicide compared to the general population [10, 142] , perhaps the highest odds of all substances. Indeed, estimates of lifetime suicide attempt rates among individuals with OUD are gravely elevated, ranging between 17% and 48% [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] .

Co-use of alcohol and opioids can significantly increase the risk of death from overdoses due to respiratory depression [153] , and in fact, many OUD-related deaths involve alcohol use [154] . There are a number of predisposing risk factors that contribute to both AUD and OUD, and some pharmacological treatments are indicated for both AUD and OUD (e.g., naltrexone). However, despite the high cooccurrence of AUD and OUD [155] , research on the contribution of this comorbidity to suicide risk is lacking. The below review therefore primarily concerns research on the cooccurrence of OUD and suicidality, without specifically accounting for comorbidity with other substances.

The association between OUD and increased suicide risk may be attributed to several factors. Social and environmental disadvantages, such as lack of family support, unemployment, and homelessness [144, [156] [157] [158] are highly prevalent among persons with OUD, as well as suicidal individuals. Childhood trauma (e.g., physical or sexual abuse) is a particularly significant early risk factor for suicide [159] and is highly prevalent in OUD [160] [161] [162] . Indeed, a history of childhood abuse significantly increase the risk for suicidal behavior in individuals OUD [144, 149, 157] .

In addition, suicide may be an extreme expression of the negative affective states [163] that result from the neurobiological changes associated with chronic opioid use [164] [165] [166] . Around 75% of individuals dependent on opioids meet criteria for at least one comorbid psychiatric diagnosis [167, 168] , predominantly mood and anxiety disorders (35-50%). These rates are much higher than those in the general population [169] , and are associated with worse psychosocial and medical status and poorer outcome in OUD [168, 170] . Both OUD and mood and anxiety disorders may share common risk factors, including genetic liability or environmental stressors [171] . Alternatively, psychiatric comorbidities in OUD may result from tolerance and neuroadaptations to chronic opioids use [164] [165] [166] 172] . Moreover, because opioids often alleviate emotional, as well as physical, pain, they provide a powerful source of negative reinforcement [173] in the self-medication of negative affective states [174] . The negative reinforcement of psychological pain in opioid use is itself a risk factor for suicidal behavior [175] , since with increasing levels of distress, patients may reach a point wherein suicide is perceived to be the only means of escape [163, 176, 177] .

Chronic opioid use leads to increasing tolerance, which is associated with allostatic changes to limbic and striatal brain circuitry. These alterations may cause persistent and escalating negative affect [165] , thereby contributing to the mental pain that frequently precedes or accompanies suicidal behavior [176] [177] [178] . Opioid-induced aversive mental states, a possible byproduct of changes to neural connectivity, are characterized by increased sensitivity to negative emotions, greater stress and pain, and decreased sensitization to natural rewards [164, 165] . Enhanced amygdala activation is one possible correlate of suicidal ideation in OUD, since amygdala activity is implicated in negative emotional reactivity in healthy adults [179, 180] and suicidal ideation in depressed patients [181, 182] . Individuals with OUD have enhanced activation of the amygdala in response to emotional faces [166] , relative to controls. Alternatively, persistent negative affective states associated with OUD may disrupt inhibitory control functions, increasing the likelihood that individuals with OUD act on their suicidal impulses. Compared to healthy controls, patients with OUD show impairments in several domains of executive control and decision-making [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] that are also linked to an increased risk for suicidal behavior [194] . Specifically, dlPFC and orbitofrontal cortex (OFC) in OUD show lower gray matter volume [195] [196] [197] , damage to white matter [198] [199] [200] [201] and decreased resting-state functional connectivity [195, [202] [203] [204] , compared with healthy controls. Further, when engaging in tasks requiring response inhibition [205, 206] , OUD patients exhibit impaired activation of dlPFC and dorsal anterior cingulate cortex, which are involved in inhibitory control and cognitive regulation of emotions [207] . These impairments may result in dysfunctional decision-making [208] , and are also linked to lifetime history of suicidal behavior [209] [210] [211] [212] .

Some evidence points to the specific role of kappa opioid receptors in mediating negative affective states in OUD. The euphoric effects of most abused opioids (e.g., heroin, oxycodone, and morphine) are due to their mu receptors agonism [213] . Chronic opioid use, tolerance, and stress may mobilize the kappa receptors system [214, 215] . Animal studies suggest that an activated kappa receptor system is a key mediator of dysphoria-related symptoms and depressive-like behavior [215] [216] [217] [218] [219] [220] , both relevant to mood disorders and chronic drug use/dependence [221] [222] [223] [224] [225] [226] [227] [228] . In humans, increased expression of kappa receptors has been found postmortem in the brains of suicide victims [229] . Moreover, kappa receptors availability in the amygdala-anterior cingulate-striatal circuitry were shown to mediate the phenotypic expression of dysphoria [230] .

Reduced serotonergic functioning, implicated in the pathophysiology of depression and suicidality [62, 63] , may also play a role in OUD [231] . Serotonin availability at postsynaptic 5-HT1 A receptors modulates pain levels by inhibiting firing of sensory neurons. Opioid drugs enhance this effect by overriding GABA-mediated inhibitory control of serotonergic neurons, causing increased serotonin release that contributes to the drug's analgesic effects. Additionally, activation of 5-HT1 A receptors modulates dopamine transmission, thereby inhibiting the reinforcing or euphoric effects of opioids [232] . Over time, opioid abuse may lead to adaptive changes in the brain that impair serotonergic modulation of pain and reward, resulting in increased pain sensitivity and opioid dependence [231, 233] .

Acute Stabilization Clinical guidelines recommend initiating pharmacological treatment for opioid withdrawal (e.g., methadone) in an inpatient setting or opioid treatment program, particularly for individuals presenting with suicidal ideation or other unmanaged psychiatric symptoms [234, 235] . Individuals with OUD frequently present to the emergency room with complications from opioid use, including withdrawal-related symptoms or overdose [236] , and therefore emergency room-based intervention reflects a key point of linkage to care for this population.

Pharmacological Interventions Few medications are available for prevention of relapse in OUD. Methadone is a long-acting full opioid receptor agonist that has been long used for treatment of individuals with OUD [237] . Although methadone treatment in persons with OUD and comorbid depression may lead to modest improvement in depressive symptoms, they often require antidepressant medications to produce meaningful reductions in depressed mood [237] . Additionally, while a recent epidemiological study reported that individuals receiving methadone experienced a 40% reduction in SB compared to periods when they were not on the medication [238] , other studies show that patients may continue to experience SI or engage in SB (e.g., overdose) while on methadone [239] . Extended-release naltrexone hydrochloride (XR-NTX) is a nonselective opioid receptor antagonist that has been also widely used for treatment of OUD and AUD, among other indications. Although initial dysphoria and anxiety have been reported when starting treatment with naltrexone, presumably a result of unmasking symptoms of psychiatric distress concealed by daily intake of opioids, these symptoms gradually subside in participants adherent to treatment [240] [241] [242] [243] [244] [245] [246] [247] . Some studies report an improvement in depressive symptoms in patients with OUD after 4 weeks of adherence to naltrexone treatment [242, 246] .

Buprenorphine, a mu opioid receptor partial agonist and kappa receptor antagonist, has become one of the most prescribed treatments for OUD relapse prevention in the US [248, 249] . Induction of buprenorphine in the emergency room for individuals with OUD who present with opioid overdoses has been shown to decrease the risk for future overdose [250] . Interestingly, buprenorphine has shown efficacy in treating depressive symptoms during the course of treatment of OUD [251] , as well as in treatment-resistant depression [252] [253] [254] . Additionally, buprenorphine has shown promise in reducing suicidal ideation [255, 256] . Some case reports reported significant reduction in suicidal ideation with the start of buprenorphine treatment for OUD [257, 258] . Even in individuals without OUD, Yovell et al. [259] found that a very low dose of buprenorphine (0.1-0.8 mg/day) significantly reduced suicidal ideation in 2 weeks, compared with placebo. Interestingly, prior studies provided evidence for the rapid antidepressant and anti-suicidal action of buprenorphine, which seemed to act within a week after the first administration [252, 254, 258, [260] [261] [262] [263] [264] . Collectively, this may support the beneficial effect of buprenorphine as a rapid-acting treatment for highrisk suicidal individuals, particularly in those with OUD. Accumulating evidence suggests that kappa antagonism properties of buprenorphine may underlie its antisuicidal properties via reducing negative affect responses in the amygdala and enhancing activity of regulatory frontal regions. In preclinical models of depression, buprenorphine produced antidepressant and anxiolytic responses [265] [266] [267] [268] driven by its kappa antagonist properties [267, 268] . More specifically, agonism to the amygdala kappa receptors mediated anxiogenic-like behavior [269] whereas antagonism to kappa receptors in the amygdala [269, 270] and prefrontal cortex [271] produced anxiolytic effects. Relative to controls, patients with OUD treated with buprenorphine demonstrated reduced amygdala activation in response to negative stimuli [272] . In addition, buprenorphine causes decreased amygdala responses to heroin-related cues in heroin-dependent patients [273] .

Psychotherapeutic Interventions There is some evidence to support the incremental utility of psychosocial interventions in combination with pharmacotherapy for OUD [274, 275] . These interventions include contingency management (CM) and other cognitive-behavioral therapies (CBT), as well as supportive psychotherapy [276] . In opioid-using adolescents and young adults, motivational enhancement therapy (MET) and CBT, as well as combined MET/CBT, have demonstrated efficaciousness in compared to a community reinforcement approach, although findings appeared to be mediated by sex and age [277] . Other meta-analytic work conclude that structured psychosocial interventions contribute little to opiate substitution programs beyond the routine counseling provided with pharmacological treatment [278] . However, such studies do not account for the utility of psychosocial treatment in reducing suicidal ideation and behavior in individuals with OUD, and research on psychosocial interventions for opioid use and co-occurring suicidality remains an outstanding area of study.

Alcohol and opioid use are the two most common substances implicated in suicidal behavior [14•]. This review briefly surveys the literature on the overlap of these disorders, highlighting the complex and multidirectional relationships between them. A meaningful understanding of the different roles that alcohol and opioid use can play in suicidal behavior, however, will require continued study of their shared risk factors, mechanisms, and interventions. For example, further empirical research is necessary to differentiate the acute effects of alcohol and opioid intake on suicidality, separably from chronic or dependent use. Additionally, the gaps in intervention research on co-occurring suicidality and AUD/OUD are substantial, and pharmacological studies do not frequently account for the effects on suicidality, specifically, in addition to mood improvements in mood, in alcohol/opioid users. Given the high prevalence of alcohol/opioid use alongside escalating rates of suicide, there is a compelling need for attention to their cooccurrence. 

The association between alcohol misuse and suicidal behaviour

Adolescent alcohol involvement and suicide attempts: toward the development of a conceptual framework

World Health Organization (WHO) 2014 global status report on alcohol and health

Assigning time-linked exposure status to controls in unmatched case-control studies: alcohol use and nearly lethal suicide attempts

Suicide as escape from self

Suicide as psychache: a clinical approach to selfdestructive behavior: Jason Aronson

Role of impulsivity in the relationship between depression and alcohol problems among emerging adult college drinkers

Toward a clinical model of suicidal behavior in psychiatric patients

A brain-centric model of suicidal behavior

The relationship of impulsive aggressiveness to suicidality and other depression-linked behaviors

Understanding the construct of impulsivity and its relationship to alcohol use disorders

Impulsive-aggressive traits, serotonin function, and alcohol-enhanced aggression

The neurodevelopmental origins of suicidal behavior

The effect of multiple adverse childhood experiences on health: a systematic review and meta-analysis

Is impulsivity a link between childhood abuse and suicide? Compr Psychiatry

Alcohol-related intimate partner violence among white, black, and Hispanic couples in the United States

Correlates of intimate partner violence among male alcoholic patients

Economic loss and alcohol consumption and problems during the 2008 to 2009 US recession

The public health effect of economic crises and alternative policy responses in Europe: an empirical analysis

Near-term predictors of the intensity of suicidal ideation: an examination of the 24 h prior to a recent suicide attempt

Suicide and suicide risk

Completed suicide at age 50 and over

Suicidality among older male veterans in the United States: results from the National Health and Resilience in Veterans Study

Roles of physical and mental health in suicidal ideation in Canadian Armed Forces Regular Force veterans

Physical disability and suicidal ideation: a community-based study of risk/protective factors for suicidal thoughts

Accelerated aging and motor control deficits are related to regional deformation of central cerebellar white matter in alcohol use disorder

Behavioral impulsivity mediates the relationship between decreased frontal gray matter volume and harmful alcohol drinking: a voxel-based morphometry study

Premature aging in male alcoholics:"accelerated aging" or "increased vulnerability

Executive functions, memory, and social cognitive deficits and recovery in chronic alcoholism: a critical review to inform future research

Suicidal behaviour and memory: a systematic review and meta-analysis

The neurobiology of suicide

Lower cerebrospinal fluid 5-hydroxyindolacetic levels in depressed high-lethality suicide attempters with comorbid alcoholism

Serotonin and aggression and the alcohol-aggression relationship

Serotonergic and noradrenergic neurobiology of alcoholic suicide

The biochemistry of affective disorders

Serotonin receptors in depression: from A to B

Aggressivity, suicide attempts, and depression: relationship to cerebrospinal fluid monoamine metabolite levels

Alcohol and central serotonin metabolism in man

Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior

Neurobiology of suicidal behaviour

Serotonin transporter gene polymorphisms, alcoholism, and suicidal behavior

Association analysis of a regulatory variation of the serotonin transporter gene with severe alcohol dependence

Serotonin transporter gene variants in alcohol-dependent subjects with dissocial personality disorder

Opposite effects of suicidality and lithium on gray matter volumes in bipolar depression

Prefrontal cortical thickness in depressed patients with high-risk for suicidal behavior

Brain structure in adolescents and young adults with alcohol problems: systematic review of imaging studies

The effect of alcohol consumption on the adolescent brain: A systematic review of MRI and fMRI studies of alcohol-using youth

Reduced hippocampal volume among adolescents with alcohol use disorders without psychiatric comorbidity

Decreased volume of the brain reward system in alcoholism

Prefrontal cortex volumes in adolescents with alcohol use disorders: unique gender effects

Neural correlates associated with suicide and non-suicidal self-injury in youth

A diffusion tensor imaging study of suicide attempters

Multimodal neuroimaging of frontolimbic structure and function associated with suicide attempts in adolescents and young adults with bipolar disorder

Altered white matter integrity in adolescent binge drinkers

Longitudinal changes in white matter integrity among adolescent substance users

Neurotoxic effects of alcohol in adolescence

Heavy alcohol use, rather than alcohol dependence, is associated with dysregulation of the hypothalamic-pituitary-adrenal axis and the autonomic nervous system

Alcohol use, urinary cortisol, and heart rate variability in apparently healthy men: evidence for impaired inhibitory control of the HPA axis in heavy drinkers

Effect of chronic alcohol consumption on the activity of the hypothalamic-pituitary-adrenal axis and pituitary β-endorphin as a function of alcohol intake, age, and gender

The dexamethasone suppression test and suicide prediction

Suicidal subtypes, stress responsivity and impulsive aggression

Toward fine-grained phenotyping of suicidal behavior: the role of suicidal subtypes

Adrenocortical hyperactivity in depression: effects of agitation, delusions, melancholia, and other illness variables

Toward subtyping of suicidality: brief suicidal ideation is associated with greater stress response

Cortisol secretion patterns in addiction and addiction risk

Alcohol, stress, and glucocorticoids: from risk to dependence and relapse in alcohol use disorders

High cortisol responders to stress show increased sedation to alcohol compared to low cortisol responders: an alcohol dose-response study

Hypothalamicpituitary-adrenal axis dysfunction as a neurobiological correlate of emotion dysregulation in adolescent suicide

Functional subsets of serotonergic neurones: implications for control of the hypothalamic-pituitary-adrenal axis

Fluoxetine trial in suicidal depressed alcoholics

Depressed patients with co-occurring alcohol use disorders: a unique patient population

Comparison of 3190 alcohol-dependent individuals with and without suicide attempts

Interventions in suicidal alcoholics

Disproportionate suicidality in patients with comorbid major depression and alcoholism

Recent suicide attempt and the effectiveness of inpatient and outpatient substance use disorder treatment

How does active substance use at psychiatric admission impact suicide risk and hospital length-of-stay?

Discharged from a mental health admission ward: is it safe to go home? A review on the negative outcomes of psychiatric hospitalization

Comorbid depression and alcohol use disorders and prospective risk for suicide attempt in the year following inpatient hospitalization

Substance use-disorder treatment and a decline in attempted suicide during and after treatment

Impulsive suicide attempts predict post-treatment relapse in alcohol-dependent patients

Depression in the primary care setting

Suicidal behavior in mood disorders: response to pharmacological treatment

What are the treatment options for comorbid alcohol abuse and depressive disorders

An integrative review summarizing empirical research on various approaches to the assessment and treatment of patients with co-occurring alcohol use disorders and depressive disorders

Anxiety, depression, and insomnia among adults with opioid dependence treated with extended-release naltrexone vs buprenorphine-naloxone: a randomized clinical trial and follow-up study

Double-blind fluoxetine in depressed alcoholic smokers

Efficacy of antidepressants in substance use disorders with and without comorbid depression: a systematic review and meta-analysis

0706743720915420. An important systematic metanalytic review of 32 placebo-controlled randomized controlled trials investigating the effects of antidepressants in the treatment of co-occurring alcohol/substance use disorders and mood disorders

The role of selective serotonin reuptake inhibitors in reducing alcohol consumption

Role of cortical alpha-2 adrenoceptors in alcohol withdrawal-induced depression and tricyclic antidepressants

Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a metaanalysis of placebo-controlled randomized trials

Co-occurring MDD and problematic alcohol use The Massachusetts General Hospital Guide to Depression

Double-blind clinical trial of sertraline treatment for alcohol dependence

Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis

Antidepressants for the treatment of people with co-occurring depression and alcohol dependence

Unhelpful prescribing in alcohol use disorder: risk and averting risk

A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence

Comparison of the safety planning intervention with follow-up vs usual care of suicidal patients treated in the emergency department

Suicide prevention in an emergency department population: the ED-SAFE study

Motivational enhancement therapy (alcohol, marijuana, nicotine)

Mechanisms of change in motivational interviewing: A review and preliminary evaluation of the evidence

Dual recovery therapy: blending psychotherapies for depression and addiction: Integrated Treatment for Mood and Substance Disorders

Psychological interventions for alcohol misuse among people with co-occurring depression or anxiety disorders: a systematic review

Evaluation of cognitive behavioral therapy/motivational enhancement therapy (CBT/MET) in a treatment trial of comorbid MDD/AUD adolescents

Contingency management for treatment of substance use disorders: a meta-analysis

Randomized controlled trial of cognitive-behavioural therapy for coexisting depression and alcohol problems: short-term outcome

Comorbid alcoholism and depression: treatment issues

Illicit drug use, illicit drug use disorders, and drug overdose deaths in metropolitan and nonmetropolitan areas-United States

Suicide: a silent contributor to opioid-overdose deaths

An editorial perspective on the need to address the role of suicidality in opioid-related deaths

Suicide deaths with opioid poisoning in the United States: 1999-2014

Suicide as an outcome for mental disorders. A meta-analysis

Are non-fatal opioid overdoses misclassified suicide attempts?Comparing the associated correlates

Risk factors for attempting suicide in heroin addicts

Suicidality in opioiddependent subjects

Attempted suicide among entrants to three treatment modalities for heroin dependence in the Australian Treatment Outcome Study (ATOS): prevalence and risk factors

Suicide risk of heroin dependent subjects in Lebanon

OPRM1 polymorphism and lifetime suicide attempts among stabilized, methadone-maintained outpatients

Suicide attempts in treated opiate addicts

Attempted suicide, self-harm, and violent victimization among regular illicit drug users

Patterns and correlates of attempted suicide amongst heroin users: 11-year follow-up of the Australian treatment outcome study cohort

Suicide attempts prior to starting methadone maintenance treatment in Taiwan

Alcohol and opioid use, co-use, and chronic pain in the context of the opioid epidemic: a critical review

Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse-related emergency department visits and drug-related deaths-United States

Rising prevalence of comorbid alcohol and opioid use disorders in adolescents and young adults in the United States

Suicide risk in depressed methadone-maintained patients: associations with clinical and demographic characteristics

Characteristics of opiate dependent patients who attempt suicide

Suicide among heroin users: rates, risk factors and methods

Childhood trauma and suicide attempt: a meta-analysis of longitudinal studies from the last decade

Prevalence of victimization and posttraumatic-stress-disorder among women with substance use disorders-comparison of telephone and in-person assessment samples

Child sexual abuse as a predictor of psychiatric co-morbidity and its implications for drug and alcohol treatment

The prevalence of childhood trauma among those seeking buprenorphine treatment

Suicidal ideation is associated with individual differences in prescription opioid craving and cue-reactivity among chronic pain patients

Opioids, pain, the brain, and hyperkatifeia: a framework for the rational use of opioids for pain

The downward spiral of chronic pain, prescription opioid misuse, and addiction: cognitive, affective, and neuropsychopharmacologic pathways

Acute effects of heroin on negative emotional processing: relation of amygdala activity and stress-related responses

Depression among needle exchange program and methadone maintenance clients

The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients

Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication

Psychiatric comorbidity in opiate addicts

Mood and anxiety disorders and their association with nonmedical prescription opioid use and prescription opioid-use disorder: longitudinal evidence from the National Epidemiologic Study on Alcohol and Related Conditions

Pleasure into pain: the consequences of long-term opioid use

Negative reinforcement in drug addiction: the darkness within

The self-medication hypothesis of substance use disorders: a reconsideration and recent applications

Reasons for suicide attempts in a clinical sample of active duty soldiers

Psychological pain: a review of evidence

The suicidal mind

Pain and suicidality: insights from reward and addiction neuroscience

Neural systems for recognizing emotion

Emotion circuits in the brain

Restingstate functional connectivity of the amygdala in suicide attempters with major depressive disorder

Amygdala functional connectivity in female patients with major depressive disorder with and without suicidal ideation

Neuropsychological consequences of chronic opioid use: a quantitative review and meta-analysis

Abnormal frontal activations related to decision-making in current and former amphetamine and opiate dependent individuals

Differences in orbitofrontal activation during decision-making between methadone-maintained opiate users, heroin users and healthy volunteers

Impulsivity and opioid drugs: differential effects of heroin, methadone and prescribed analgesic medication

Impaired decision making in opiate addiction correlates with anxiety and selfdirectedness but not substance use parameters

Opioid abuse and cognitive performance

Cognitive impairment in methadone maintenance patients

Profile of executive deficits in cocaine and heroin polysubstance users: common and differential effects on separate executive components

Cognitive impulsivity in cocaine and heroin polysubstance abusers

Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls

Heroin and cocaine abusers have higher discount rates for delayed rewards than alcoholics or non-drugusing controls

A meta-analysis of neuropsychological markers of vulnerability to suicidal behavior in mood disorders

Altered gray matter volume and disrupted functional connectivity of dorsolateral prefrontal cortex in men with heroin dependence

Prefrontal and temporal gray matter density decreases in opiate dependence

Gray matter deficits and restingstate abnormalities in abstinent heroin-dependent individuals

Disrupted white matter integrity in heroin dependence: a controlled study utilizing diffusion tensor imaging

Methadone-induced damage to white matter integrity in methadone maintenance patients: a longitudinal self-control DTI study

White matter hyperintensities in subjects with cocaine and opiate dependence and healthy comparison subjects

Progressive white matter microstructure damage in male chronic heroin dependent individuals: a DTI and TBSS study

Addiction related alteration in restingstate brain connectivity

Dysfunctional connectivity patterns in chronic heroin users: an fMRI study

Heroin abuse accelerates biological aging: a novel insight from telomerase and brain imaging interaction

Impaired response inhibition function in abstinent heroin dependents: an fMRI study

Inferior frontal cortex modulation with an acute dose of heroin during cognitive control

Cognitive reappraisal of emotion: a meta-analysis of human neuroimaging studies

Decision-making processes following damage to the prefrontal cortex

Are structural brain abnormalities associated with suicidal behavior in patients with psychotic disorders?

Structural brain abnormalities and suicidal behavior in borderline personality disorder

Positron emission tomography of regional brain metabolic responses to a serotonergic challenge and lethality of suicide attempts in major depression

Regional brain glucose uptake distinguishes suicide attempters from non-attempters in major depression

Reward processing by the opioid system in the brain

Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects

Social defeat stress-induced behavioral responses are mediated by the endogenous kappa opioid system

The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system

Antidepressantlike effects of kappa-opioid receptor antagonists in the forced swim test in rats

Antidepressant-like effects of kappa-opioid receptor antagonists in Wistar Kyoto rats

Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats

Prior activation of kappa opioid receptors by U50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning

Kappa opioid receptors regulate stress-induced cocaine seeking and synaptic plasticity

Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking

Behavioral stress may increase the rewarding valence of cocaine-associated cues through a dynorphin/kappa-opioid receptor-mediated mechanism without affecting associative learning or memory retrieval mechanisms

The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors

The dynorphin/ kappa-opioid receptor system and its role in psychiatric disorders

Role of kappa-opioid receptors in stress and anxiety-related behavior

Dynorphin/kappa-opioid receptor control of dopamine dynamics: implications for negative affective states and psychiatric disorders

Prodynorphin mRNA expression is increased in the patch vs matrix compartment of the caudate nucleus in suicide subjects

Association of in vivo kappa-opioid receptor availability and the transdiagnostic dimensional expression of trauma-related psychopathology

Availability of dopamine and serotonin transporters in opioid-dependent users-a two-isotope SPECT study

Serotonin-1A receptor dependent modulation of pain and reward for improving therapy of chronic pain

Adaptations in responsiveness of brainstem pain-modulating neurons in acute compared with chronic inflammation

National practice guideline for the use of medications in the treatment of addiction involving opioid use

American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use

Emergency department initiation of buprenorphine for opioid use disorder: current status, and future potential

What we have learned from the Methadone Maintenance Treatment of Dual Disorder Heroin Use Disorder patients

Medications for alcohol and opioid use disorders and risk of suicidal behavior, accidental overdoses, and crime

Suicidal risk among patients enrolled in methadone maintenance treatment: HCV status and implications for suicide prevention (ANRS Methaville)

Long-term opioid blockade and hedonic response: preliminary data from two open-label extension studies with extendedrelease naltrexone

Naltrexone alters the processing of social and emotional stimuli in healthy adults

Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant

Naltrexone and dysphoria: fact or myth?

The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study The Naltrexone Usage Study Group

Effect of extendedrelease naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients

The association between naltrexone treatment and symptoms of depression in opioid-dependent patients

Findings from a randomized controlled trial in subjects with opioid dependence

National and state treatment need and capacity for opioid agonist medication-assisted treatment

Trends in buprenorphine treatment in the United States

Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence

Anxiety, depression, and insomnia among adults with opioid dependence treated with extended-release naltrexone vs buprenorphine-naloxone: a randomized clinical trial and follow-up study

Buprenorphine treatment of refractory depression

Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy

2410 A multisite randomized double-blind placebo-controlled trial investigating the efficacy and safety of very low dosages of sublingual buprenorphine as a time-limited treatment for severe suicidal ideation

Evaluation of 6 remote First Nations community-based buprenorphine programs in northwestern Ontario: retrospective study

Comparison of abuse, suspected suicidal intent, and fatalities related to the 7-day buprenorphine transdermal patch versus other opioid analgesics in the National Poison Data System

The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial

The anti-suicidal potential of buprenorphine: a case report

Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: a randomized controlled trial

Possible antidepressive effects of opioids: action of buprenorphine

Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults

Evaluation of opioid modulation in major depressive disorder

Depressive symptoms during buprenorphine treatment of opioid abusers

Eight-milligram single dose of buprenorphine as an expeditious treatment for severe suicidal ideation: a case report

Antidepressant-like effects of buprenorphine in rats are strain dependent

Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice

Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice

Antidepressant-like effects of buprenorphine are mediated by kappa opioid receptors

CRF1-R activation of the dynorphin/kappa opioid system in the mouse basolateral amygdala mediates anxiety-like behavior

Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats

Prefrontal cortical kappa opioid receptors attenuate responses to amygdala inputs

Functional imaging of emotion reactivity in opiate-dependent borderline personality disorder

Acute effects of sublingual buprenorphine on brain responses to heroin-related cues in early-abstinent heroin addicts: an uncontrolled trial

A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction

The role of behavioral interventions in buprenorphine maintenance treatment: a review

Pharmacological and behavioral treatment of opioid use disorder

Addressing the opioid epidemic with behavioral interventions for adolescents and young adults: a quasi-experimental design

Psychosocial interventions in opiate substitution treatment services: does the evidence provide a case for optimism or nihilism?

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations